SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996
This article was originally published in The Gray Sheet
Executive Summary
SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996 is planned by the Bothell, Washington-based company, CEO Steven Quay, MD/PhD, told a Medical Investments Northwest conference in Seattle Sept. 12. A total of 45 patients of a planned 120 have completed Phase II trials, which began July 10. Initial indications will be diagnosis of cardiovascular disease, renal vascular disease/hypertension, and cancer, Quay said.